M&B 39890A, a novel sulphonamido-benzamide compound, inhibits insulin and glucagon secretion in vitro.

  title={M\&B 39890A, a novel sulphonamido-benzamide compound, inhibits insulin and glucagon secretion in vitro.},
  author={Ramona A. Silvestre and Elena Peir{\'o} and Paloma Miralles and Jos{\'e} Marco},
  journal={Biochemical pharmacology},
  volume={38 15},
1 Citations
New hypoglycaemic agents.
  • B. Hulin
  • Medicine
    Progress in medicinal chemistry
  • 1994


Inhibition of Glucagon Secretion by Diazoxide In Vitro
Diazoxide inhibits the secretion of glucagon as well as insulin in response to certain secretagogues independent of any changes in prevailing levels of glucose, and at the concentration tested, diazoxide is a more potent and consistent inhibitor of the release of insulin than of glucagons.
Effects of galanin on hormone secretion from the in situ perfused rat pancreas and on glucose production in rat hepatocytes in vitro.
Galanin inhibited insulin secretion without modifying glucagon and somatostatin output, thus pointing to a direct effect of galanin on the B cell; and in rat hepatocytes, Galanin did not affect glycogenolysis or gluconeogenesis; hence, the reported hyperglycemia induced by exogenous galan in does not seem to be accounted for by a directEffect of this peptide on hepatic glucose production.
Glucagon and insulin release by the in vitro perfused rat pancreas
It is suggested that unidentified factor(s) present in some albumin preparations may affect the secretory responsiveness of the endocrine pancreas.
Coated charcoal immunoassay of insulin.
The procedure here described yields a straight line graph when insulin added is plotted against insulin recovered, and makes simpler and more rapid the immunoassay of insulin in biologic fluids, using radioisotope dilution with 131I-insulin and "biopsy" of the insulin pool by antibody to insulin.
Measurements of somatostatin-like immunoreactivity in plasma.